ReviewTheranostics2025
Exosomes: innovative biomarkers leading the charge in non-invasive cancer diagnostics.
Review in Theranostics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Exosomes in diabetic kidney disease: pathogenesis, biomarker discovery, and emerging therapeutics-a comprehensive systematic review.Renal failure · 2026Pooled it
- Exosomes and Triple-Negative Breast Cancer: Current Knowledge and Clinical Significance.International journal of molecular sciences · 2026Pooled it
- mRNA-based therapeutics in lung Cancer: Mechanisms, applications, and translational challenges.Journal, genetic engineering & biotechnology · 2026Review
- A Panel of Circulating Exosomal sncRNAs Associated With Lung Cancer Risk up to 10 Years in Advance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Nanotechnology in Pediatric Neurology: Applications and Innovations.Pharmaceutics · 2026Review
- Review
- Exosomes in precision dermatology: From biomarkers to targeted therapeutics in personalized care.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Review
- A Candidate Salivary miRNA Panel for Bronchopulmonary Dysplasia in Very and Extremely Low-Birth-Weight Preterm Infants: A Pilot Exploratory Study.Life (Basel, Switzerland) · 2026Article
- Article
- Artificial Intelligence-Enabled Exosomes in Precision Oncology: A Framework for Clinical Utility and Biomedical Applications.Current issues in molecular biology · 2026Review
- Review
- Exosomal microRNAs in Periodontitis: From Molecular Footprints to Clinical Frontiers.ACS pharmacology & translational science · 2026Review
- Electrochemical liquid biopsy across cancer care pathway.The journal of liquid biopsy · 2026Review
- Plant Exosome Injection with or without Low Level Laser Therapy Promotes Skin Wound Healing: An Experimental Study.Plastic and reconstructive surgery. Global open · 2026Article
- Article
- Early Detection and Inhibition of Post-Surgical Cancer Recurrence by Synthetic Extracellular Vesicles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- T-Cell Exhaustion in the Tumor Microenvironment: Subcellular Dysfunction, Pan-Cancer Characteristics, and Therapeutic Interventions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Exosomes as Disease-Informed Nanoplatforms for Pulmonary Fibrosis: From Pathogenic Signaling to Precision Diagnosis and Therapy.Pharmaceutics · 2026Review
- State-of-the-Art Applications of Field-Effect Transistor Biosensors in Exosome Detection: A Comprehensive Review.Biosensors · 2026Review
- Exosomal circ0000549 promotes MNNG‑induced gastric cancer through miR‑15b‑5p/KIF1B.International journal of molecular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exosomes, nanoscale extracellular vesicles secreted by diverse cell types, have emerged as promising biomarkers for non-invasive tumor diagnostics, offering significant advantages over traditional methods. These vesicles, typically ranging from 30 to 150 nanometers in size, carry a diverse cargo of proteins, lipids, RNA, and microRNAs, which reflect the molecular alterations occurring within their parent cells. Notably, exosomes can be isolated from easily accessible biofluids such as blood, urine, and saliva, making them ideal candidates for liquid biopsy applications. This review explores the transformative potential of exosome-based biomarkers in the early detection and monitoring of cancers across diverse organ systems, including respiratory, digestive, hematological, neurological, endocrine malignancies and so on. Special emphasis is placed on their application in clinical trials, where exosome-based diagnostics have demonstrated promising results in detecting tumors at early stages and monitoring treatment responses, offering a less invasive and more accessible alternative to traditional biopsies. While recent advancements in exosome isolation and characterization technologies have significantly improved the sensitivity and specificity of these diagnostics, challenges such as biological heterogeneity, lack of standardization, and regulatory hurdles remain. Nevertheless, exosome-based diagnostics hold the promise of providing real-time, dynamic insights into tumor progression, enhancing personalized medicine. The integration of exosomes into clinical practice could revolutionize cancer diagnostics and therapy, improving patient outcomes. Further research and large-scale clinical validation are essential to fully realize the clinical potential of exosome-based biomarker applications in routine clinical settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.